Study of an injection for moderate to severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests an investigational drug (SIM0278) given as an injection to see if it helps reduce eczema symptoms. It is for people with moderate to severe atopic dermatitis who have not used certain other treatments recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a doctor's diagnosis of atopic dermatitis (eczema).
- You are willing to use a moisturizer on your eczema at least twice a day for at least a week before starting.
- You have not taken a biologic for your immune system (like IL-2 inhibitors) in the past.
- You have not used certain other immune medicines or phototherapy (light treatment) in the past few weeks or months.
- You are willing to use birth control during the study and for 90 days after your last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medication (HXN6005) for people with moderate-to-severe eczema that hasn't been controlled by topical treatments. The goal is to see if the drug is safe and effective in reducing eczema symptoms.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This study tests a new injected medication called XKH001 for people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't improved with standard creams. The goal is to see if it can reduce the severity of eczema and itching.
This study tests an injection called ADSTEM for people with moderate to severe eczema (atopic dermatitis) that hasn't improved with standard creams or other treatments. The goal is to see if it can help reduce symptoms like itching and rash.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.